Merck’s Vytorin Litigation Saga Ends With $688 Million Securities Class Action Settlements
This article was originally published in The Pink Sheet Daily
Executive Summary
Investors alleged they lost money from the nearly two-year delay in release of results of the Enhance trial; Merck and Schering previously paid $5.4 million to states to resolve Enhance investigation.
You may also be interested in...
Merck Clinical Trial Compliance Settlement Relies On Board Oversight
For a three-year period Merck will inform a committee of its board if trial results are not reported within 12 months; the agreement resolves a shareholder derivative suit claiming Schering directors caused results of the Vytorin ENHANCE trial to be suppressed.
Merck, Schering-Plough Dodge Vytorin Enforcement Bullet
In settlement with state attorneys general, the companies agree to pay $5.4 million to cover investigative costs and recommit to routine oversight policies.
Companies Reveal Hurdles In Providing Drugs Via Expanded Access Programs
GSK, Stealth BioTherapeutics and Blueprint Medicines discuss the difficulties getting participation of physicians, the excessive cost of expanded access, and whether physicians should report research data.